TY - JOUR
T1 - Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients
AU - Guiot, Julien
AU - Henket, Monique
AU - Gester, Fanny
AU - André, Béatrice
AU - Ernst, Benoit
AU - Frix, Anne-Noelle
AU - Smeets, Dirk
AU - Van Eyndhoven, Simon
AU - Antoniou, Katerina
AU - Conemans, Lennart
AU - Gote-Schniering, Janine
AU - Slabbynck, Hans
AU - Kreuter, Michael
AU - Sellares, Jacobo
AU - Tomos, Ioannis
AU - Yang, Guang
AU - Ribbens, Clio
AU - Louis, Renaud
AU - Cottin, Vincent
AU - Tomassetti, Sara
AU - Smith, Vanessa
AU - Walsh, Simon L F
PY - 2025/1/24
Y1 - 2025/1/24
N2 - Background: Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapidly evolving interstitial lung disease (ILD), driving its mortality. Specific imaging-based biomarkers associated with the evolution of lung disease are needed to help predict and quantify ILD. Methods: We evaluated the potential of an automated ILD quantification system (icolung
®) from chest CT scans, to help in quantification and prediction of ILD progression in SSc-ILD. We used a retrospective cohort of 75 SSc-ILD patients to evaluate the potential of the AI-based quantification tool and to correlate image-based quantification with pulmonary function tests and their evolution over time. Results: We evaluated a group of 75 patients suffering from SSc-ILD, either limited or diffuse, of whom 30 presented progressive pulmonary fibrosis (PPF). The patients presenting PPF exhibited more extensive lesions (in % of total lung volume (TLV)) based on image analysis than those without PPF: 3.93 (0.36–8.12)* vs. 0.59 (0.09–3.53) respectively, whereas pulmonary functional test showed a reduction in Force Vital Capacity (FVC)(pred%) in patients with PPF compared to the others : 77 ± 20% vs. 87 ± 19% (p < 0.05). Modifications of FVC and diffusing capacity of the lungs for carbon monoxide (DLCO) over time were correlated with longitudinal radiological ILD modifications (r=-0.40, p < 0.01; r=-0.40, p < 0.01 respectively). Conclusion: AI-based automatic quantification of lesions from chest-CT images in SSc-ILD is correlated with physiological parameters and can help in disease evaluation. Further clinical multicentric validation is necessary in order to confirm its potential in the prediction of patient’s outcome and in treatment management.
AB - Background: Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapidly evolving interstitial lung disease (ILD), driving its mortality. Specific imaging-based biomarkers associated with the evolution of lung disease are needed to help predict and quantify ILD. Methods: We evaluated the potential of an automated ILD quantification system (icolung
®) from chest CT scans, to help in quantification and prediction of ILD progression in SSc-ILD. We used a retrospective cohort of 75 SSc-ILD patients to evaluate the potential of the AI-based quantification tool and to correlate image-based quantification with pulmonary function tests and their evolution over time. Results: We evaluated a group of 75 patients suffering from SSc-ILD, either limited or diffuse, of whom 30 presented progressive pulmonary fibrosis (PPF). The patients presenting PPF exhibited more extensive lesions (in % of total lung volume (TLV)) based on image analysis than those without PPF: 3.93 (0.36–8.12)* vs. 0.59 (0.09–3.53) respectively, whereas pulmonary functional test showed a reduction in Force Vital Capacity (FVC)(pred%) in patients with PPF compared to the others : 77 ± 20% vs. 87 ± 19% (p < 0.05). Modifications of FVC and diffusing capacity of the lungs for carbon monoxide (DLCO) over time were correlated with longitudinal radiological ILD modifications (r=-0.40, p < 0.01; r=-0.40, p < 0.01 respectively). Conclusion: AI-based automatic quantification of lesions from chest-CT images in SSc-ILD is correlated with physiological parameters and can help in disease evaluation. Further clinical multicentric validation is necessary in order to confirm its potential in the prediction of patient’s outcome and in treatment management.
KW - Artificial intelligence
KW - Computed tomography
KW - Interstitial lung disease
KW - Pulmonary function tests
KW - Systemic sclerosis
KW - Humans
KW - Scleroderma, Systemic/complications diagnostic imaging
KW - Lung Diseases, Interstitial/diagnostic imaging physiopathology diagnosis
KW - Female
KW - Male
KW - Middle Aged
KW - Retrospective Studies
KW - Aged
KW - Artificial Intelligence
KW - Tomography, X-Ray Computed/methods
KW - Predictive Value of Tests
KW - Cohort Studies
KW - Adult
KW - Respiratory Function Tests/methods
KW - Lung/diagnostic imaging physiopathology
U2 - 10.1186/s12931-025-03117-9
DO - 10.1186/s12931-025-03117-9
M3 - Article
SN - 1465-9921
VL - 26
JO - Respiratory Research
JF - Respiratory Research
IS - 1
M1 - 39
ER -